There are many types of asthma inhalers. They differ in whether they're used for quick relief or long-term control, what type ...

GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

Incruse Ellipta (umeclidinium) is a brand-name inhaler prescribed for chronic obstructive pulmonary disease (COPD) in adults. As with other drugs, Incruse Ellipta can cause side effects ...

But while topline results, published in May, suggest its new drug Relvar Ellipta is a step forward in treatment, the full trial data paints a more down-to-earth reality – with some disappointing ...

Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Umeclidinium 62.5mcg; per inhalation; dry pwd for oral inhalation; contains lactose. Incruse Ellipta should be stored at room temperature between 68°-77° F (20°-25° C); excursions permitted ...

This open line of communication led his doctor to prescribe TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder), a once-daily treatment for ...

Mumbai: Global pharma major Lupin Limited (Lupin) recently announced the appointment of Claus Jepsen as President, Global ...

GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.

Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate ...